Heritage Investors Management Corp Sells 94 Shares of Eli Lilly and Company $LLY

Heritage Investors Management Corp trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,204 shares of the company’s stock after selling 94 shares during the quarter. Heritage Investors Management Corp’s holdings in Eli Lilly and Company were worth $939,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. O Brien Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after acquiring an additional 12 shares during the period. Ascent Capital Management LLC boosted its position in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock valued at $409,000 after acquiring an additional 12 shares during the period. Willner & Heller LLC boosted its position in shares of Eli Lilly and Company by 1.5% in the first quarter. Willner & Heller LLC now owns 854 shares of the company’s stock valued at $705,000 after acquiring an additional 13 shares during the period. Braun Bostich & Associates Inc. boosted its position in shares of Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after acquiring an additional 13 shares during the period. Finally, Rise Advisors LLC boosted its position in shares of Eli Lilly and Company by 1.8% in the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after acquiring an additional 13 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 3.5%

LLY stock opened at $842.28 on Friday. The company has a market cap of $797.18 billion, a PE ratio of 55.05, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. The business has a 50-day simple moving average of $777.69 and a 200 day simple moving average of $770.84. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s payout ratio is presently 39.22%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LLY. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Finally, Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $936.47.

Insider Activity

In other Eli Lilly and Company news, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.